```
Ac-pAph-Chg-Arg-Gla-Pro-NH<sub>2</sub>; Ac-pAph-Chg-Arg-Cys (CH<sub>2</sub>-COOH) - Pro-NH<sub>2</sub>;
Ac-Pal(4)Me-Chg-Arg-Leu-Pro-NH<sub>2</sub>; Ac- (iBu) Nal (2) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
Ac-Phe (p-CONH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
Ac-pAph-Chg-Arg-N [1(1,3-dicarboxy) propyl)] Gly-Pro-NH<sub>2</sub>;
Ac-pAph-Chg-Dap (CH=N(CH<sub>3</sub>)<sub>2</sub>) -Leu-Pro-NH<sub>2</sub>;
(2-quinolinoyl) -Phe (NH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
Ac-pAph-Chg-Arg-N (carboxymethyl) Gly-Pro-NH<sub>2</sub>;
Ac-pAph-Chg-Arg- (carboxyethyl) Gly-Pro-NH<sub>2</sub>; Ac-mAph-Chg-Arg-Leu-Pro-NH<sub>2</sub>;
Alloc-pAph-Chg-PalMe(3) -Pen (CH<sub>2</sub>COOH)-Pro-NH<sub>2</sub>;
Ac-pAph-Chg-Arg-N [1(1,3-dicarboxy) propyl)] Gly-Pro-NH<sub>2</sub>;
Ac-pAph-Ile-Arg-Leu-Pro-NH<sub>2</sub>; Ac-Phe (pNH<sub>2</sub>) -Chg-Arg- (Me) Leu-Pro-NH<sub>2</sub>;
Ac- (Chx-CH<sub>2</sub>) Tyr-Chg-Arg-Leu-Pro-NH<sub>2</sub>;
(3-pyridoyl) -Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
(3-pyridoyl) -Nal (2) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
Ac-Pal(4)Me-Chg-Pal(4)Me-Leu-Pro-NH<sub>2</sub>; Alloc-pAph-Chg-Arg-Leu-Pro-NH<sub>2</sub>;
(4-isoquinolinoyl) -Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
Ac-pAph-Cha-PalMe(3) - (Me) Leu-Pro-NH<sub>2</sub>;
Ac-pAph-Chg-PalMe(3) -Leu-Pro-NH<sub>2</sub>;
(2-naphythl-CH<sub>2</sub>) Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
(5-pyrazinoyl) Nal (2) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
(Benzoyl) - Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
Ac- (2-methylpentanyl) -Tyr-Ile-Arg-Leu-Pro-NH<sub>2</sub>;
(2-pyridonyl) Phe (pNH<sub>2</sub>) Chg-Arg-Leu-Pro-NH<sub>2</sub>;
(Benzoyl) -Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub>;
Ac- (2-methypentyl) Tyr-Ile-Arg-Leu-Pro-NH<sub>2</sub>;
```

Ac- (iBu) Phe (pCN) -Chg-Arg-Leu-Pro-NH₂;

Application No. 09/211,715
Reply to Advisory Action of July 2, 2003

Ac- (Chx-CH₂) -Tyr-lle-Arg-Leu-Pro-NH₂.

September 10, 2003 S&L File No. P26,835-D USA

Ac- (2-methybutyl) Tyr-Ile-Arg-Leu-Pro-NH₂;

Ac-Phe (pNH₂) -Chg-Arg-Leu-Pro-NH₂; Ac-Phe (pNH₂) -Chg-Arg-Leu-Hyp-NH₂;

Ac-Tyr-Chg-Arg-Leu-Pro-NH₂;

(2-naphthylsulfonyl) -Phe (pNH₂) -Chg-Arg-Leu-Pro-NH₂;

(2-methylbenzyl) -Phe (pNH₂) -Chg-Arg-Leu-Pro-NH₂;

(2-benzofuroyl) -Phe(pNH₂) -Chg-Dab (CH=N(CH₃)₂) -Leu-Pro-NH₂;

Ac- (cyclopentenyl-CH₂) Tyr-Ile-Arg-Leu-Pro-NH₂;

Ac-Pal (4) Me-Chg-PalMe(3) -Leu-Pro-NH₂;

Ac- (iBu) -Phe (pNH₂) -Chg-Arg-Leu-Pro-NH₂; and

- Claim 9 (Previously presented): A compound selected from the group consisting of Ac-pAph-Chg-Arg-Leu-NH₂ and Ac-pAph-Chg-Arg-Leu.
- Claim 10 (Previously presented): A compound selected from the group consisting of (2-benzofuroyl) -pAph-Chg-PalMe(3) -NH₂ and Ac- (iBu) Phe (pNH₂) -Chg-Arg-NH₂.
- Claim 1/ (Currently amended): A compound selected from the group consisting of Alloc-pAph-Chg-PalMe(3) -NH₂;

 (2-quinolinoyl) -pAph-Chg-PalMe(3) -NH₂;

 Ac-pAph-Chg-PalMe(3) -NH (1-methoxycarbonyl) -1-cyclohexyl;

 Ac-pAph-Chg-Arg-NH₂; (2-pyridoyl) -pAph-Chg-PalMe(3) -NH₂;

 CF₃C(O) (iBu) Phe (pNH₂) -Chg-Arg-NH₂;

 Ac-pAph-Chg-PalMe(3) -NH- (1-methoxycarbonyl) -1-cyclopentyl;

 Ac-pAph-Chg-PalMe(3) -NH- (4-methoxycarbonyl-cyclohexyl) methyl;

Application No. 09/211,715
Reply to Advisory Action of July 2, 2003

September 10, 2003 S&L File No. P26,835-D USA

Ac-pAph-Chg-PalMe(3) -NH- (3-thienyl-2-carboxylic acid methyl ester);

Ac-pAph-Chg-Arg-NH₂; CF₃C(O) - (iBu) Tyr-Chg-Arg- OH COOH;

Ac-pAph-Chg-PalMe(3) -NH- (4-methoxycarbonyl-cyclohexyl) methyl;

Ac-pAph-Chg-PalMe(3) -NH₂; Ac-pAph-Chg-Pal(3) (CH₂COOH) -NH₂;

(2-quinolinecarboxy) -pAph-Chg-PalMe(3)-NH₂;

Ac-pAph-Chg-PalMe(3) -NH- (4-carboxycyclohexyl) methyl; and

CF₃C (O) (iBu) -Tyr-Ile-Arg-NH₂.

Claims 12-19 (Canceled)

Claim 20 (Previously presented): A compound selected from the group consisting of Ac-D-pAph-Chg-Arg-Leu-Pro-NH₂;

Ac-D-pAph-Chg-Arg-Gla-Pro-NH₂;

Ac-D-pAph-Chg-Arg-Cys (CH₂-COOH) -Pro-NH₂;

Ac-D-pAph-Chg-Arg-N (carboxymethyl) Gly-Pro-NH₂;

Ac-D-pAph-Chg-Arg- (carboxyethyl) Gly-Pro-NH₂;

Ac-D-pAph-Chg-Arg-N [1(1,3-dicarboxy) propyl)] Gly-Pro-NH₂;

Ac-D-pAph-Ile-Arg-Leu-Pro-NH₂; Alloc-D-pAph-Chg-Arg-Leu-Pro-NH₂;

Ac-D-pAph-Chg-PalMe(3) -Leu-Pro-NH₂; and Ac-D-pAph-Chg-Arg-NH₂.

Claim 21 (Previously presented): A compound Ac-D-pAph-Chg-PalMe(3) -Leu-Pro-NH₂.

Claim 22 (Previously presented): A compound Ac-D-pAph-Chg-PalMe(3) -NH₂.

Application No. 09/211,715 Reply to Advisory Action of July 2, 2003 September 10, 2003 S&L File No. P26,835-D USA

Claim 23/(Original): A compound Ac-Phe (pNH₂) -Chg-Arg-Leu-Pro-NH₂.

Claim 24 (Canceled)

Claim 25 (Previously presented): A method of specifically inhibiting the activity of Factor Xa, comprising contacting the factor Xa with the compound as in claims 7, 8, 9, 10, 11, 20, 21, 22, or 23.

Claim 26 (Canceled)